Correspondence 0001193125-24-133076 from HilleVax, Inc. (HLVX) (CIK 0001888012)
HilleVax, Inc. (HLVX) (CIK 0001888012)
Date: May 7, 2024 · CIK: 0001888012 · Accession: 0001193125-24-133076
AI Filing Summary & Sentiment
File numbers found in text: 333-278110
Letter
HilleVax, Inc.
321 Harrison Avenue
Boston, MA 02118
May 7, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: HilleVax, Inc.
Registration Statement on Form S-3
File No. 333-278110
To the addressees set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of HilleVax, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 9, 2024, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
Very truly yours,
HILLEVAX, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP HilleVax, Inc. 321 Harrison Avenue Boston, MA 02118 May 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HilleVax, Inc. Registration Statement on Form S-3 File No. 333-278110 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of HilleVax, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 9, 2024, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter. Very truly yours, HILLEVAX, INC. By: /s/ Robert Hershberg, M.D., Ph.D. Robert Hershberg, M.D., Ph.D. President and Chief Executive Officer cc: Paul Bavier, HilleVax, Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP